ABIOMED Inc
NASDAQ:ABMD
Intrinsic Value
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ABMD.
ABIOMED Inc's market capitalization is 17.2B USD.
ABMD stock price is 381.02 USD.
ABMD.
ABMD. Open DCF Valuation
ABMD. Open Relative Valuation
ABMD.
ABMD's ROE (Return on Equity) has decreased in the last 3 years from 19% to 18%.
ABMD's ROIC (Return on Invested Capital) has increased in the last 3 years from 22% to 23%.
ABMD's Revenue has grown by 10% over the past 12 months.
ABMD's ROE (Return on Equity) for the past 12 months is positive and is equal to 18%.
ABMD's Revenue is forecast to grow at a rate of 14% per year over the next 3 years.
ABMD's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 23%.
ABMD has positive Net Income for the last twelve months.
ABMD has positive three-year average ROE (Return on Equity): 17%. The company is efficient at transforming stockholders' equity into net income.
ABMD has positive Operating Income for the last twelve months.
ABMD has positive three-year average ROIC (Return on Invested Capital): 25%. The company is efficient at using invested capital to generate operating income.
ABMD has positive Gross Profit for the last twelve months.
ABMD has positive Free Cash Flow for the last twelve months.
ABMD's short-term assets (1B USD) exceed its short-term liabilties (134m USD).
ABMD's long-term assets (2B USD) exceed its long-term liabilties (157m USD).
ABMD's D/E (Debt to Equity) is very low and is equal to 0.
ABMD's Altman Z-Score is very high and is equal to 44.61.
Fundamental Analysis
ABIOMED Inc
Balance Sheet Decomposition
ABIOMED Inc
| Current Assets | 1.1B |
| Cash & Short-Term Investments | 820.4m |
| Receivables | 94.5m |
| Other Current Assets | 148m |
| Non-Current Assets | 633.7m |
| Long-Term Investments | 289.1m |
| PP&E | 202.7m |
| Intangibles | 123.1m |
| Other Non-Current Assets | 18.9m |
| Current Liabilities | 134.1m |
| Accounts Payable | 35.1m |
| Accrued Liabilities | 66.6m |
| Other Current Liabilities | 32.4m |
| Non-Current Liabilities | 22.7m |
| Other Non-Current Liabilities | 22.7m |
Earnings Waterfall
ABIOMED Inc
|
Revenue
|
1.1B
USD
|
|
Cost of Revenue
|
-200.6m
USD
|
|
Gross Profit
|
873.5m
USD
|
|
Operating Expenses
|
-619.4m
USD
|
|
Operating Income
|
254.1m
USD
|
|
Other Expenses
|
12.7m
USD
|
|
Net Income
|
266.8m
USD
|
Free Cash Flow Analysis
ABIOMED Inc
ABMD Profitability Score
Profitability Due Diligence
ABIOMED Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Score
ABIOMED Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
ABMD Solvency Score
Solvency Due Diligence
ABIOMED Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
ABIOMED Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABMD Price Targets Summary
ABIOMED Inc
Ownership
ABMD Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ABMD Price
ABIOMED Inc
| Average Annual Return | 27.26% |
| Standard Deviation of Annual Returns | 85.38% |
| Max Drawdown | -53% |
| Market Capitalization | 17.2B USD |
| Shares Outstanding | 45 091 200 |
| Percentage of Shares Shorted | 2.16% |
ABMD News
Last Important Events
ABIOMED Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
ABIOMED Inc
Company Profile
ABIOMED Inc
Country
Industry
Market Cap
Dividend Yield
Description
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company is headquartered in Danvers, Massachusetts and currently employs 1,725 full-time employees. The firm develops, manufactures and markets its products, which are designed to improve blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. Its operating segment includes the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. Its existing products include Impella 2.5, Impella CP, Impella 5.0 and Impella LD. The Impella 2.5 device is a percutaneous micro heart pump with an integrated motor and sensors. The Impella CP device provides blood flow of approximately one liter more per minute than the Impella 2.5 device.
You don't have any saved screeners yet
